Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.891274
Keywords
SARS-CoV-2; COVID19; IEI; activated PI3K delta syndrome (APDS); monoclonal antibody; remdesivir; long-lasting infection; APDS
Categories
Funding
- Fondo 5x1000
Ask authors/readers for more resources
This case demonstrates the good tolerability and efficacy of monoclonal antibodies in reducing viral shedding in long-lasting infections refractory to other treatments. The virus was cleared 7 days after monoclonal antibody administration, showing the effectiveness of this treatment option.
We described the case of a patient affected by activated PI3K-kinase delta syndrome (APDS) and a long-lasting and pauci-symptomatic SARS-CoV-2 infection, treated with multiple therapeutic agents including remdesivir and SARS-CoV-2-neutralizing monoclonal antibodies. We detected the clearance of the virus 105 days from the first positive swab and 7 days after monoclonal antibody administration. At genotyping, the SARS-CoV-2 virus resulted as wild type on all samples tested. This case shows the monoclonal antibodies' good tolerability and efficacy in reducing viral shedding in long-lasting infections refractory to other treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available